CryoPort (NASDAQ:CYRX) Trading Up 9.1% - Should You Buy?

Key Points

• CryoPort's stock price rose by 9.1%, reaching a last traded price of $10.17, despite a significant decline in trading volume of 91% from average levels.
• A number of analysts have upgraded CryoPort's stock recommendations, with price targets set between $13.00 and $16.00, reflecting a consensus rating of "Moderate Buy" and a target price of $12.56.
• CryoPort reported a revenue of $45.45 million for its last quarter, surpassing expectations, although it posted a net loss of ($0.29) earnings per share (EPS), missing estimates by ($0.09).

Shares of CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) traded up 9.1% during trading on Wednesday . The company traded as high as $9.94 and last traded at $10.17. 48,284 shares traded hands during trading, a decline of 91% from the average session volume of 538,172 shares. The stock had previously closed at $9.32.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Stephens assumed coverage on shares of CryoPort in a research note on Tuesday, July 22nd. They set an "overweight" rating and a $13.00 price objective for the company. BTIG Research upped their target price on CryoPort from $10.00 to $15.00 and gave the company a "buy" rating in a report on Thursday, September 18th. KeyCorp upgraded CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 target price on the stock in a report on Wednesday, August 6th. Leerink Partners upgraded CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 price objective on the stock in a report on Wednesday, August 6th. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of CryoPort in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $12.56.

CryoPort Trading Up 7.9%

The company's fifty day moving average price is $9.16 and its two-hundred day moving average price is $7.44. The company has a current ratio of 16.24, a quick ratio of 15.47 and a debt-to-equity ratio of 0.39. The firm has a market cap of $503.45 million, a P/E ratio of 7.56 and a beta of 1.61.

CryoPort (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09). CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. The business had revenue of $45.45 million during the quarter, compared to the consensus estimate of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other CryoPort news, Director Robert J. Hariri sold 25,000 shares of the firm's stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $9.71, for a total transaction of $242,750.00. Following the transaction, the director owned 51,275 shares in the company, valued at approximately $497,880.25. This trade represents a 32.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ramkumar Mandalam sold 40,728 shares of CryoPort stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of $7.24, for a total value of $294,870.72. Following the transaction, the director owned 92,328 shares in the company, valued at $668,454.72. This trade represents a 30.61% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 80,028 shares of company stock worth $661,252. Insiders own 10.10% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC increased its holdings in shares of CryoPort by 299.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company's stock worth $27,000 after acquiring an additional 2,729 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in CryoPort by 300.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company's stock valued at $44,000 after purchasing an additional 4,375 shares during the period. ProShare Advisors LLC bought a new stake in CryoPort in the 2nd quarter valued at $75,000. Avanza Fonder AB boosted its stake in CryoPort by 31.4% in the 2nd quarter. Avanza Fonder AB now owns 10,882 shares of the company's stock valued at $81,000 after purchasing an additional 2,601 shares during the period. Finally, PharVision Advisers LLC bought a new stake in CryoPort in the 2nd quarter valued at $82,000. 92.90% of the stock is owned by institutional investors and hedge funds.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.